20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
The Oncology Institute, Inc. (STLN) operates in the MEDICAL CARE FACILITIES industry and is headquartered in Cerritos, United States with about 641 employees. Its market capitalization is roughly $646 million. In the fiscal year ended 2025-12-31, STLN reported $503M in revenue and ($61M) in net income.
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other.
Interactive charts & full statements → Open the STLN valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $587M | $503M | $393M | $324M | $252M |
| Gross Profit | $92M | $76M | $54M | $60M | $52M |
| Gross Margin % | 15.7% | 15.2% | 13.7% | 18.4% | 20.6% |
| Operating Income (EBIT) | ($26M) | ($36M) | ($60M) | ($60M) | ($72M) |
| Operating Margin % | -4.4% | -7.2% | -15.3% | -18.6% | -28.5% |
| Net Income | ($36M) | ($61M) | ($65M) | ($83M) | $0M |
| Net Margin % | -6.2% | -12.1% | -16.4% | -25.6% | 0.1% |
| EBITDA | ($22M) | ($43M) | — | — | — |
| Earnings Per Share (EPS) | $-0.36 | $-0.66 | $-0.85 | $-1.12 | $0.00 |
| Shares Outstanding (M) | 103M | 92M | 76M | 74M | 73M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $161M | $147M | $142M | $137M | $120M | $104M |
| Gross Profit | $27M | $23M | $23M | $19M | $18M | $17M |
| Gross Margin % | 16.8% | 15.8% | 16.0% | 13.9% | 14.6% | 16.5% |
| Operating Income (EBIT) | ($5M) | ($7M) | ($7M) | ($8M) | ($11M) | ($10M) |
| Operating Margin % | -2.9% | -4.4% | -4.9% | -5.9% | -9.4% | -9.5% |
| Net Income | ($10M) | ($2M) | ($8M) | ($17M) | ($17M) | ($20M) |
| Net Margin % | -6.1% | -1.7% | -5.3% | -12.1% | -14.2% | -18.8% |
| EBITDA | ($6M) | $1M | ($4M) | ($13M) | — | — |
| Earnings Per Share (EPS) | $-0.10 | $-0.02 | $-0.07 | $-0.17 | $-0.18 | $-0.22 |
| Shares Outstanding (M) | 103M | 102M | 101M | 97M | 93M | 89M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Cash from Operations (CFO) | $0M | ($25M) | ($27M) | ($36M) | ($62M) |
| Capital Expenditures (CapEx) | $4M | $3M | $4M | $5M | $6M |
| Free Cash Flow (FCF) | ($3M) | ($28M) | ($30M) | ($41M) | ($67M) |
| FCF Margin % | -0.6% | -5.5% | -7.7% | -12.6% | -26.7% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $12M | ($2M) | $3M | ($13M) | ($10M) | ($5M) |
| Capital Expenditures (CapEx) | $1M | $1M | $1M | $1M | $1M | $0M |
| Free Cash Flow (FCF) | $11M | ($3M) | $2M | ($13M) | ($11M) | ($5M) |
| FCF Margin % | 6.8% | -2.2% | 1.5% | -9.7% | -9.5% | -5.1% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets | $178M | $165M | $173M | $209M | $262M |
| Cash & Cash Equivalents | $41M | $34M | $50M | $33M | $14M |
| Total Liabilities | $203M | $180M | $169M | $152M | $138M |
| Total Debt (Short + Long-Term) | $87M | $85M | $93M | $87M | $81M |
| Total Shareholders' Equity | ($25M) | ($16M) | $4M | $57M | $123M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive STLN viewer.
About TickerBase · Data methodology & sources · Privacy · Terms